We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Research on the Environment and Children's Health: Retinoblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00582049
Recruitment Status : Completed
First Posted : December 28, 2007
Last Update Posted : July 4, 2008
Information provided by:

Study Description
Brief Summary:
The purpose of the research study is to learn more about the causes of retinoblastoma and to identify possible risk factors in the parents of patients with retinoblastoma. This kind of study is called an epidemiology study and is often done by interviewing people with and without the disease. In the case of a childhood disease, the researchers ask about experiences of the parents and children before the disease developed.

Condition or disease

Detailed Description:
The purpose of the study is to investigate the role of paternal exposures in the etiology of sporadic heritable retinoblastoma (RBL). The study has a matched case-control design with a sample size of 255 pairs. Cases will be children with sporadic heritable (RBL) identified from eight hospitals that together treat most of the RBL patients in the U.S. and Canada. We will use regional controls matched on year of birth and state/province of residence identified by randomdigit-dialing (RDD). Fathers and mothers of cases and controls will be interviewed by telephone about their occupational, medical, dietary, and personal exposures before the index child's conception. Blood samples will be obtained on cases and their parents for DNA isolation. The case's DNA will be used to characterize the disease-causing RB1 mutation. The parent's DNA will be used to detect the few instances in which a parent also has the RB1 mutation, i.e., the child's RBL is familial rather than sporadic.

Study Design

Study Type : Observational
Estimated Enrollment : 78 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Research on the Environment and Children's Health: Retinoblastoma
Study Start Date : August 2003
Primary Completion Date : June 2008
Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Cases: retinoblastoma patients
Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).

Outcome Measures

Primary Outcome Measures :
  1. demographic and exposure information by telephone interview [ Time Frame: 5 years 4 months ]

Biospecimen Retention:   Samples With DNA

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The subjects (cases) will be children with sporadic heritable RBL and their parents. Parents of children without RBL will be identified and will participate as controls.

Inclusion Criteria:

  • Cases will be children with sporadic heritable RBL, i.e., bilateral RBL without a family history of the disorder.
  • Cases will be diagnosed with retinoblastoma in an approximately 7-year period, beginning January 1, 1998 and continuing until the sample size is reached.
  • The case family must reside in the continental U.S., Alaska, or Canada.
  • The case family must have a telephone in the household.
  • The patient's physician must give permission to contact the parents of the case.
  • The biologic father or mother of the case must be available and consent to be interviewed.
  • The father or mother must speak English or Spanish.
  • Genetic counseling regarding RB1 gene mutation analysis must be done prior to registration onto study.

Exclusion Criteria:

- Cases that do not meet the above criteria will be ineligible to participate and excluded from the study.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00582049

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
University of Pennsylvania
New York Presbyterian Hospital
Milton S. Hershey Medical Center
Principal Investigator: Ira Dunkel, MD Memorial Sloan Kettering Cancer Center
More Information

Additional Information:
Responsible Party: Ira Dunkel, MD, Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00582049     History of Changes
Other Study ID Numbers: 03-030
First Posted: December 28, 2007    Key Record Dates
Last Update Posted: July 4, 2008
Last Verified: June 2008

Keywords provided by Memorial Sloan Kettering Cancer Center:
Sporadic heritable retinoblastoma
Paternal exposures

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Retinal Neoplasms
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Retinal Diseases